RetaCalc
Protocol library
SingleInvestigationalEarly HumanLow confidenceSourced

Ipamorelin

A ghrelin-receptor agonist with early human pharmacology and an intravenous phase 2 postoperative study. Neither establishes a routine subcutaneous wellness protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Human Study
Adults after bowel resection in a phase 2 hospital trial

0.03 mg/kg by intravenous infusion twice daily from postoperative day 1 through day 7 or discharge

This was an inpatient postoperative ileus study and did not establish subcutaneous or long-term use.

View source
Human Study
Healthy male volunteers

Single 15-minute intravenous infusions across five dose-escalation cohorts

This pharmacology experiment measured short-term growth-hormone release rather than a clinical outcome.

View source

Evidence summary

A ghrelin-receptor agonist with early human pharmacology and an intravenous phase 2 postoperative study. Neither establishes a routine subcutaneous wellness protocol.

Protocol basis

The page reports the actual intravenous study designs and makes the route mismatch visible instead of translating them into subcutaneous units.

What remains uncertain

A validated outpatient indication, subcutaneous exposure, long-term safety and clinical benefit are not established.

Warnings and contraindications

The best clinical outcome trial used intravenous infusions in hospital patients.
Growth-hormone responses do not prove meaningful clinical benefit.
A subcutaneous research vial does not match the studied intravenous formulation.